ML-based sequential analysis to assist selection between VMP and RD for newly diagnosed multiple myeloma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Sung-Soo | - |
dc.contributor.author | Lee, Jong Cheol | - |
dc.contributor.author | Byun, Ja Min | - |
dc.contributor.author | Choi, Gyucheol | - |
dc.contributor.author | Kim, Kwan Hyun | - |
dc.contributor.author | Lim, Sungwon | - |
dc.contributor.author | Dingli, David | - |
dc.contributor.author | Jeon, Young-Woo | - |
dc.contributor.author | Yahng, Seung-Ah | - |
dc.contributor.author | Shin, Seung-Hwan | - |
dc.contributor.author | Min, Chang-Ki | - |
dc.contributor.author | Koo, Jamin | - |
dc.date.accessioned | 2023-06-01T09:40:20Z | - |
dc.date.available | 2023-06-01T09:40:20Z | - |
dc.date.created | 2023-06-01 | - |
dc.date.issued | 2023-12-01 | - |
dc.identifier.issn | 2397-768X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hongik/handle/2020.sw.hongik/31195 | - |
dc.description.abstract | Optimal first-line treatment that enables deeper and longer remission is crucially important for newly diagnosed multiple myeloma (NDMM). In this study, we developed the machine learning (ML) models predicting overall survival (OS) or response of the transplant-ineligible NDMM patients when treated by one of the two regimens-bortezomib plus melphalan plus prednisone (VMP) or lenalidomide plus dexamethasone (RD). Demographic and clinical characteristics obtained during diagnosis were used to train the ML models, which enabled treatment-specific risk stratification. Survival was superior when the patients were treated with the regimen to which they were low risk. The largest difference in OS was observed in the VMP-low risk & RD-high risk group, who recorded a hazard ratio of 0.15 (95% CI: 0.04-0.55) when treated with VMP vs. RD regimen. Retrospective analysis showed that the use of the ML models might have helped to improve the survival and/or response of up to 202 (39%) patients among the entire cohort (N = 514). In this manner, we believe that the ML models trained on clinical data available at diagnosis can assist the individualized selection of optimal first-line treatment for transplant-ineligible NDMM patients. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | NATURE PORTFOLIO | - |
dc.subject | BORTEZOMIB-MELPHALAN-PREDNISONE | - |
dc.subject | INTERNATIONAL STAGING SYSTEM | - |
dc.subject | EARLY RELAPSE | - |
dc.subject | DEXAMETHASONE RD | - |
dc.subject | LENALIDOMIDE | - |
dc.subject | THERAPY | - |
dc.subject | TRANSPLANT | - |
dc.subject | SURVIVAL | - |
dc.subject | RISK | - |
dc.subject | OUTCOMES | - |
dc.title | ML-based sequential analysis to assist selection between VMP and RD for newly diagnosed multiple myeloma | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Koo, Jamin | - |
dc.identifier.doi | 10.1038/s41698-023-00385-w | - |
dc.identifier.scopusid | 2-s2.0-85160092664 | - |
dc.identifier.wosid | 000991246200001 | - |
dc.identifier.bibliographicCitation | NPJ PRECISION ONCOLOGY, v.7, no.1 | - |
dc.relation.isPartOf | NPJ PRECISION ONCOLOGY | - |
dc.citation.title | NPJ PRECISION ONCOLOGY | - |
dc.citation.volume | 7 | - |
dc.citation.number | 1 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | BORTEZOMIB-MELPHALAN-PREDNISONE | - |
dc.subject.keywordPlus | INTERNATIONAL STAGING SYSTEM | - |
dc.subject.keywordPlus | EARLY RELAPSE | - |
dc.subject.keywordPlus | DEXAMETHASONE RD | - |
dc.subject.keywordPlus | LENALIDOMIDE | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | TRANSPLANT | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | OUTCOMES | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
94, Wausan-ro, Mapo-gu, Seoul, 04066, Korea02-320-1314
COPYRIGHT 2020 HONGIK UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.